Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead Makes Headway With Merck 'Unclean Hands' Argument

Executive Summary

A federal judge reopened a patent infringement case after finding an "unclean hands" argument compelling enough to consider, in which Gilead Sciences Inc. alleged one of Merck & Co. Inc.'s patent attorneys had lied about not being on a confidential conference call where chemical structure details about the predecessor to Sovaldi were discussed.

You may also be interested in...

Merck Gets $200m In Gilead Patent Case, But Who Wins?

A jury in the US District Court for the Northern District of California, which decided earlier in the week that Gilead Sciences Inc. infringed two of Merck & Co. Inc.'s hepatitis C drug patents, determined on March 24 that Gilead should pay its rival $200m – a sum much lower than what Merck sought when the companies' patent dispute began in 2013.

Merck Hep C Drug Zepatier OK'd

Merck & Co. gained the FDA's go-ahead on Jan. 28 to market Zepatier (elbasvir and grazoprevir) as a treatment for adults with chronic hepatitis C virus (HCV) genotypes (GTs) 1 or 4 infection, with or without ribavirin (RBV).

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts